Remove Disease Remove Specialty Pharmacies Remove Therapies
article thumbnail

Informa Connect's Hub and Specialty Pharmacy Models West

Drug Channels

Informa Connect's Hub and Specialty Pharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Delivered as a Hybrid Event. Drug Channels readers will save 10% off the current registration rate when they use code 22DC10 *.

article thumbnail

Informa Connect’s Access USA

Drug Channels

Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and the Rare Disease Summit three influential access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships. What is Access USA?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

The Pharma Data

Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Progeria and Progeroid Laminopathies are separate and distinct ultra-rare, genetic, premature aging diseases that accelerate mortality in young patients. PALO ALTO, Calif.,

article thumbnail

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

The Pharma Data

Tyvaso in pulmonary hypertension due to interstitial lung disease (PH-ILD). Tyvaso also showed benefits across several key subgroups, including etiology of PH-ILD, disease severity, age, gender, baseline hemodynamics, and dose. Tyvaso in patients with chronic fibrosing interstitial lung disease (CFILD) — TETON.

FDA 40